title: Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
authors.affiliation: Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. m.puoti@iol.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Puoti
authors.forename: Sergio
authors.initials: S
authors.lastname: Babudieri
authors.forename: Giovanni
authors.initials: G
authors.lastname: Rezza
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Viale
authors.forename: Maria Giulia
authors.initials: MG
authors.lastname: Antonini
authors.forename: Ivana
authors.initials: I
authors.lastname: Maida
authors.forename: Stefania
authors.initials: S
authors.lastname: Rossi
authors.forename: Barbara
authors.initials: B
authors.lastname: Zanini
authors.forename: Valeria
authors.initials: V
authors.lastname: Putzolu
authors.forename: Luisa
authors.initials: L
authors.lastname: Fenu
authors.forename: Chiara
authors.initials: C
authors.lastname: Baiguera
authors.forename: Salvatore
authors.initials: S
authors.lastname: Sassu
authors.forename: Giampiero
authors.initials: G
authors.lastname: Carosi
authors.forename: Maria Stella
authors.initials: MS
authors.lastname: Mura
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007239:Infections / Q000139:chemically induced*; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007558:Italy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D011994:Recombinant Proteins; D012141:Respiratory Tract Infections / Q000139:chemically induced; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a